---
schema_version: "secwatch.filing_event.v1"
accession: "0001808665-25-000011"
form_type: "8-K"
ticker: "ASRT"
cik: "0001808665"
company_name: "Assertio Holdings, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T00:13:21.871484+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Assertio Q1 net product sales $26.0M (-18% YoY), GAAP loss $13.5M; settles DOJ qui tam, transfers opioid liabilities

## Summary
- Net product sales $26.0M vs $31.9M YoY; GAAP net loss $13.5M ($0.14 loss per share) vs $4.5M loss.
- Adjusted EBITDA $0.2M vs $7.4M YoY; adjusted EPS ($0.04) vs $0.04 positive.
- Rolvedon net sales $13.1M (-10% YoY) on lower pricing; Indocin $5.5M (-37% YoY) on generic competition.
- Settled DOJ False Claims Act lawsuit and last Glumetza antitrust action; transferred subsidiary with opioid liabilities.
- Cash $87.3M; $40M in 6.5% convertible notes due 2027; no near-term maturities.

## SEC filing metadata
- accession: 0001808665-25-000011
- form_type: 8-K
- ticker: ASRT
- cik: 0001808665
- company_name: Assertio Holdings, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808665/000180866525000011/0001808665-25-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808665/000180866525000011/asrt-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808665-25-000011
- JSON: https://secwatch.observer/filing/0001808665-25-000011.json
- Plain text: https://secwatch.observer/filing/0001808665-25-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.